Wo2020008391 Abrocitinib Manufacturing Process Patent Details
Patent application WO2020008391, published on January 9, 2020, describes a manufacturing process for abrocitinib, a Janus kinase 1 (JAK1) inhibitor used to treat atopic dermatitis [1]. The patent details a specific synthesis route that aims to provide abrocitinib in a form suitable for pharmaceutical formulation [1].
What is Abrocitinib Used For?
Abrocitinib is a medication approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents [1]. It works by inhibiting JAK1, a key enzyme involved in the inflammatory pathways of the skin condition [1].
What Does Patent WO2020008391 Cover Regarding Abrocitinib?
This patent application specifically details a method for manufacturing abrocitinib [1]. It outlines chemical steps and conditions designed to produce the active pharmaceutical ingredient efficiently and with high purity, which are critical for drug safety and efficacy [1].
Who Developed the Manufacturing Process in WO2020008391?
The patent application lists Pfizer Inc. as the applicant [1]. Pfizer Inc. is the company that developed and markets abrocitinib under the brand name Cibinqo [2].
When Does Abrocitinib Manufacturing Patent Protection End?
The specific patent application WO2020008391 is a publication of a patent application, not a granted patent [1]. The duration of patent protection for abrocitinib manufacturing processes would depend on when the full patents were granted and their respective expiry dates. Generally, patents in the United States can last up to 20 years from the filing date, with potential extensions for pharmaceutical products [3]. DrugPatentWatch.com provides detailed information on patent expiry dates and exclusivity periods for various drugs, including abrocitinib [4].
What are the Key Steps in the Abrocitinib Manufacturing Process Described?
While the full details of complex chemical synthesis are extensive, the patent WO2020008391 focuses on a process to obtain abrocitinib, likely involving multiple reaction steps and purification stages to ensure the final product meets pharmaceutical standards [1]. The aim is often to develop a robust and scalable manufacturing route [1].
Are There Other Patents Related to Abrocitinib Manufacturing?
Yes, there are likely to be multiple patents covering different aspects of abrocitinib, including its composition of matter, formulations, and potentially other manufacturing processes or intermediates [4]. Pharmaceutical companies often file numerous patents to protect their intellectual property comprehensively. Information on abrocitinib's patent landscape can be found on resources like DrugPatentWatch.com [4].
What is the Significance of a Manufacturing Process Patent?
A manufacturing process patent protects the specific methods used to create a drug [3]. This is important because even if the patent for the drug molecule itself expires, a company might still have exclusive rights to a particular, more efficient, or cost-effective way of making it, potentially delaying generic competition [3].
How Does Abrocitinib Compare to Other Treatments for Atopic Dermatitis?
Abrocitinib is a targeted therapy that differs from traditional treatments like topical corticosteroids or calcineurin inhibitors. It belongs to a class of drugs known as JAK inhibitors, which offer a different mechanism of action for controlling inflammation [1, 5]. Other JAK inhibitors are also used for atopic dermatitis and other inflammatory conditions.
Sources:
[1] WO2020008391 A1 - Method for preparing abrocitinib. https://patents.google.com/patent/WO2020008391A1/en
[2] Cibinqo (abrocitinib). https://www.cibinqo.com/
[3] Understanding Pharmaceutical Patents. U.S. Food & Drug Administration. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cdler/understanding-pharmaceutical-patents
[4] DrugPatentWatch.com https://www.drugpatentwatch.com/
[5] Abrocitinib. https://www.drugs.com/abrocitinib.html